NEW YORK (GenomeWeb News) – Luminex said after the close of the market Tuesday that it has renewed its 10-year strategic partnership with One Lambda.
The alliance, which began in 2000, is focused on developing platforms and technologies for human leukocyte antigen typing and antibody screening for the organ transplantation market. One Lamda has developed a range of HLA tests based on Luminex's xMAP technology.
According to a Luminex statement, One Lambda sells products that can detect up to 500 HLA specificities in a single test and are sold in more than 80 countries worldwide.
Financial and other terms of the agreement were not disclosed.